CompanyDrug

Junshi Biosciences’ RENOTORCH Study Meets Endpoints for RCC Treatment

CompanyDrug

Sihuan Pharmaceutical’s Birociclib Meets Primary Endpoint in Phase III Breast Cancer Study

Company

MicroPort Scientific Corp. Reports 8% Revenue Growth and Increased R&D Investment in 2022

CompanyDrug

CSPC Pharmaceutical’s Prusogliptin for Type 2 Diabetes Accepted for NMPA Review

CompanyDrug

Ocumension Therapeutics’ Zerviate Receives NMPA Priority Review for Ophthalmology Treatment

CompanyDeals

Dizal Pharma Plans to Raise $376.1 Million for Drug R&D and Industrialization

DrugPolicy / Regulatory

NMPA Mandates Label Updates for 11 Drug Varieties Including Black Box Warnings

CompanyDeals

Shanghai Fosun Pharmaceutical Reported to Halt Sale of Stake in Gland Pharma

CompanyDeals

LaNova Medicines and LegoChem Biosciences Partner to Develop Innovative ADC Product

CompanyDeals

Sunshine Guojian Pharmaceutical and Shenyang 3SBio Secure Exclusive Licensing Agreement for Antitumor Programs

CompanyDrug

Junshi Biosciences Submits Market Filings for PCSK9 mAb Ongericimab to NMPA

Policy / Regulatory

Jiangsu Initiates Price Negotiations for Provincial Stock Drugs, Addresses Shortages